Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats


Posted on: 16 Jan 18

JUPITER, Fla., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a research and development collaboration with the Israel Institute for Biological Research (“IIBR”) to further advance its C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, to combat emerging diseases and threats.

IIBR is a governmental, applied research institute specializing in the fields of biology, medicinal chemistry and environmental sciences. Backed by six decades of experience, IIBR combines highly trained personnel with cutting-edge technologies and infra-structure to conduct applied research and development in the fields of biology, medicinal chemistry and environmental sciences, in addition to basic research studies closely related to IIBR's applied projects.

http://www.iibr.gov.il/Default.aspx

“We are delighted that IIBR has selected our C1 technology for their project designed to potentially combat against emerging diseases and biological threats by deploying the C1 gene expression platform as a potential game changing technology in Israel. The objective of the program is to enable the production of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, and in high volumes and low cost,” said Mark A. Emalfarb, Founder and CEO of Dyadic. “This project will provide Dyadic with a unique opportunity to work with such a renowned organization to integrate our C1 gene expression platform into an end to end product development and manufacturing capability to produce biologics and take one or more of them through the regulatory process.  Substantially, the work will be performed at IIBR’s laboratories by using in-house resources.”

“The IIBR development program will encompass the spectrum of product and process development utilizing C1’s advanced genetic techniques and novel characteristics for the production of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies. This is a great opportunity for Dyadic to demonstrate the unique benefits of using the C1 platform,” said Ronen Tchelet, PhD, Dyadic’s VP of Research and Business Development. “We anticipate that this program, using our C1 technology, will help bring biologic products to market faster, and most importantly, create a platform that may help save lives.”

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.  Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of using these technologies in the development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.

Safe Harbor Regarding Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) Dyadic’s ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key third-party and related party research organizations, customers and collaborators; and (8) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2016, Annual Report filed with OTC Markets on March 24, 2017. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.

Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone:  561-743-8333
Email:  tdubinski@dyadic.com

GlobeNewswire
globenewswire.com

Last updated on: 17/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.